Embark Small Cap Equity Fund Q1 2025 Commentary
Source: SeekingAlpha
2025-06-11 11:19:00 ET
Performance
Average Annual Returns
Share Class | Ticker | CUSIP | 3 Months | YTD | 1 Yr. | 3 Yr. | 5 Yr. | 10 Yr. | Since Inception | Inception Date | Net Expense Ratio % | Gross Expense Ratio % |
Institutional | ESCWX | 41152J405 | -10.53% | -10.53% | -8.82% | N/A | N/A | N/A | -1.70% | 01/30/24 | 0.69 | 0.73 |
Retirement | ESCQX | 41152J306 | -10.53% | -10.53% | -8.77% | N/A | N/A | N/A | -1.66% | 01/30/24 | 0.61 | 0.65 |
Russell 2000® Index | -9.48% | -9.48% | -4.01% | N/A | N/A | N/A | 2.12% | 01/30/24 |
Read the full article on Seeking Alpha
For further details see:
Embark Small Cap Equity Fund Q1 2025 Commentary
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-4.98% G/L:
$56.52 Last:
259,831 Volume:
$58.62 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
